erlotinib hydrochloride has been researched along with dinaciclib in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (dinaciclib) | Trials (dinaciclib) | Recent Studies (post-2010) (dinaciclib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 133 | 12 | 129 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | dinaciclib (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 0.0272 | |
| Cyclin-K | Homo sapiens (human) | 0.0227 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.0162 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0742 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.049 | |
| Cyclin-A2 | Homo sapiens (human) | 0.002 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.119 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.0028 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.0074 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 0.23 | |
| Cyclin-dependent kinase 8 | Homo sapiens (human) | 0.0039 | |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 0.414 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.324 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.1273 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0227 | |
| Cyclin-H | Homo sapiens (human) | 0.17 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.17 | |
| Cyclin-A1 | Homo sapiens (human) | 0.003 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.011 | |
| Heat shock factor protein 1 | Homo sapiens (human) | 0.007 | |
| Cyclin-dependent kinase 13 | Homo sapiens (human) | 0.021 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.0219 | |
| Cyclin-dependent kinase 12 | Homo sapiens (human) | 0.0323 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bannerji, R; Edelman, MJ; Jou, YM; Joy, AA; Martin, JC; Nemunaitis, J; Small, K; Statkevich, P; Stephenson, JJ; Yao, SL; Zhang, D; Zhou, H; Zhu, Y | 1 |
1 trial(s) available for erlotinib hydrochloride and dinaciclib
| Article | Year |
|---|---|
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cyclic N-Oxides; Cyclin-Dependent Kinases; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Indolizines; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pyridinium Compounds; Quinazolines | 2014 |